# The Treatment of Glabellar Frown Lines

> **NCT02096081** · PHASE4 · COMPLETED · sponsor: **Merz North America, Inc.** · enrollment: 250 (actual)

## Conditions studied

- Glabellar Frown Lines

## Interventions

- **DRUG:** IncobotulinumtoxinA
- **DRUG:** OnabotulinumtoxinA

## Key facts

- **NCT ID:** NCT02096081
- **Lead sponsor:** Merz North America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2014-08
- **Final completion:** 2014-11
- **Target enrollment:** 250 (ACTUAL)
- **Last updated:** 2017-10-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02096081

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02096081, "The Treatment of Glabellar Frown Lines". Retrieved via AI Analytics 2026-09-07 from https://api.ai-analytics.org/clinical/NCT02096081. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*